<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662282</url>
  </required_header>
  <id_info>
    <org_study_id>00033519</org_study_id>
    <nct_id>NCT03662282</nct_id>
  </id_info>
  <brief_title>Omegaven as Alternative Parenteral Fat Nutrition</brief_title>
  <official_title>Omegaven as Alternative Parenteral Fat Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral
      nutrition associated cholestasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An intermediate population, Investigational New Drug study, to provide an alternate
      intravenous fat nutrition, Omegaven®, to help improve liver function while providing adequate
      nutrition for critically ill infants with parenteral nutrition associated cholestasis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">January 7, 2019</completion_date>
  <primary_completion_date type="Actual">January 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participant With Decrease in Direct Bilirubin Level</measure>
    <time_frame>First month of treatment</time_frame>
    <description>Number of participant with decrease in direct bilirubin levels within 30 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Resolution of Direct Hyperbilirubinemia</measure>
    <time_frame>2 months</time_frame>
    <description>Number of participant with Direct bilirubin level of &lt;2mg/dL at discontinuation of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Preservation of Length</measure>
    <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
    <description>Monitoring of weekly length while the patient is receiving Omegaven® treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Preservation of Head Circumference</measure>
    <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
    <description>Monitoring of weekly head circumference while the patient is receiving Omegaven® treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant With Preservation of Normal Weight Gain</measure>
    <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
    <description>Monitoring of daily weight gain while the patient is on Omegaven®</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cholestasis</condition>
  <condition>Cholestasis of Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Drug - Omegaven®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury</description>
    <arm_group_label>Drug - Omegaven®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 14 days old

          -  Has parenteral nutrition associated cholestasis defined as at least 2 consecutive
             direct bilirubin &gt;2 mg/dL with anatomical or functional short gut (OR &gt;4 mg/dL if
             intact intestine) obtained at least 1 week apart with a ratio of direct: total
             bilirubin &gt; 0.4

          -  Patient is parenteral nutrition dependent (unable to meet nutritional needs solely by
             enteral nutrition) and are expected to require parenteral nutrition for at least 3
             more weeks

          -  Patient has not responded to other therapeutic approaches for parenteral
             nutrition-associated liver disease such as : cycling of parenteral nutrition, avoiding
             overfeeding, reduction/removal of copper and manganese from parenteral nutrition,
             advancement of enteral feeding, and use of Ursodiol

          -  Patient has been on at least 2 weeks of SMOFLIPIDs with no improvement or worsening of
             direct bilirubin levels

          -  Signed patient informed consent

          -  The patient is expected to have a reasonable possibility of survival

          -  No other known etiology of cholestasis other than parenteral nutrition-associated
             liver disease at the time of Omegaven® initiation

        Exclusion Criteria:

          -  Known causes of cholestasis other than parenteral nutrition-associated liver disease
             including but not limited to Hepatitis C, Cystic fibrosis, biliary atresia, and alpha
             1 antitrypsin deficiency are present, prior to Omegaven® initiation

          -  Known fish or egg allergy

          -  Any of the contraindications to use of Omegaven®:

               1. Active new infection at the time of initiation of Omegaven®

               2. Hemodynamic instability

               3. Recent use of medications with associated risk of bleeding, including NSAIDs

               4. Active coagulopathy or bleeding

               5. Platelet counts persistently under 30,000 despite transfusions

               6. Unstable hyperglycemia

               7. Impaired lipid metabolism (triglycerides &gt;1000 mg/dL) while on 1 g/kg/day or less
                  of Intralipid

               8. History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease,
                  etc.)

               9. Unstable diabetes mellitus

              10. Collapse and shock

              11. Stroke/ Embolism

              12. Cardiac infarction within the last 3 months

              13. Undefined coma status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thao Ho, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>June 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omegaven</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>Liver disease</keyword>
  <keyword>Cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03662282/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants were recruited from a single NICU for compassionate use of Omegaven for cholestasis.</recruitment_details>
      <pre_assignment_details>Infants were screened based on inclusion and exclusion criteria. When there was a potential candidate, an IND application is submitted to FDA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug - Omegaven®</title>
          <description>Participants were screened based on inclusion and exclusion criteria. If and when a participant was qualified for Omegaven treatment, we sent FDA and application for IND approval. After the approval, the participant received Omegaven daily per protocol until cholestatsis resolved.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug - Omegaven®</title>
          <description>These infants were more than one month old with history of long-term TPN dependence due to intestinal problem.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="30" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant With Decrease in Direct Bilirubin Level</title>
        <description>Number of participant with decrease in direct bilirubin levels within 30 days of treatment</description>
        <time_frame>First month of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - Omegaven®</title>
            <description>Omegaven treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Decrease in Direct Bilirubin Level</title>
          <description>Number of participant with decrease in direct bilirubin levels within 30 days of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>decrease in bilirubin level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>increase or no change in bilirubin level</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Resolution of Direct Hyperbilirubinemia</title>
        <description>Number of participant with Direct bilirubin level of &lt;2mg/dL at discontinuation of treatment</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - Omegaven®</title>
            <description>Omegaven treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Resolution of Direct Hyperbilirubinemia</title>
          <description>Number of participant with Direct bilirubin level of &lt;2mg/dL at discontinuation of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>bilirubin &lt;2mg/dL at discontinuing of Omegaven</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>bilirubin &gt;2mg/dL at discontinuing of Omegaven</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Preservation of Length</title>
        <description>Monitoring of weekly length while the patient is receiving Omegaven® treatment</description>
        <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - Omegaven®</title>
            <description>Omegaven treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Preservation of Length</title>
          <description>Monitoring of weekly length while the patient is receiving Omegaven® treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Preservation of length growth</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>fail in length growth</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Preservation of Head Circumference</title>
        <description>Monitoring of weekly head circumference while the patient is receiving Omegaven® treatment</description>
        <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - Omegaven®</title>
            <description>Omegaven treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Preservation of Head Circumference</title>
          <description>Monitoring of weekly head circumference while the patient is receiving Omegaven® treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>preservation of head circumference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fail in head circumference growth</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant With Preservation of Normal Weight Gain</title>
        <description>Monitoring of daily weight gain while the patient is on Omegaven®</description>
        <time_frame>Weekly measurement during treatment. Evaluation every 30 days from treatment initiation until discontinuation of treatment, patient hospital discharge, whichever comes first, or up to 6 months following initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Drug - Omegaven®</title>
            <description>Omegaven treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Preservation of Normal Weight Gain</title>
          <description>Monitoring of daily weight gain while the patient is on Omegaven®</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>preservation of weight gain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>fail in weight gain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug - Omegaven®</title>
          <description>Omegaven treatment group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thao Ho</name_or_title>
      <organization>University of South Florida</organization>
      <phone>813-844-3437</phone>
      <email>tho1@usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

